Eye imaging study for age-related macular degeneration
Part of Eyes & vision clinical trials.
This study uses specialized eye imaging to track changes in geographic atrophy, a type of vision loss from macular degeneration. Researchers will use new imaging techniques to better understand how this condition progresses and how treatments work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 55 years or older
- You have age-related macular degeneration (AMD) or geographic atrophy (GA) in at least one eye
- If you have GA, it has not yet affected the very center of your macula (the central part of your vision)
- Your GA area is smaller than 17.5 mm² (about the size of 7 small freckles on the retina)
- You have not had anti-VEGF injections or certain retinal treatments in the study eye in the last 12 months
- You do not have other eye conditions like severe diabetic retinopathy, retinal vein/artery blockage, macular holes, or recent eye surgery
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses special eye imaging to look closely at areas of damage in the back of the eye (geographic atrophy) caused by age-related macular degeneration. It will help doctors understand early-stage disease better and may guide future treatments.
This study looks closely at how age-related macular degeneration (AMD) develops and changes over time by taking detailed eye measurements. It may help researchers better understand disease progression, especially for people who already have AMD.
This study focuses on people age 50+ with early “wasting away” changes in the macula (central retina) called atrophic lesions. It aims to better understand how these early changes progress and how they affect vision testing, which may help improve future treatments.
This trial uses artificial intelligence to track changes in the eyes of people with advanced age-related macular degeneration (AMD) that has caused a specific type of damage (atrophy) in the retina. The goal is to see if AI can help detect when the disease gets worse, so doctors can personalize monitoring for each patient.
This study looks at people with intermediate age-related macular degeneration (AMD), a common eye condition that can affect central vision. The researchers want to better understand how AMD changes over time by using different types of eye scans. This may help find ways to monitor the condition and guide future treatments.
This study tests a new way to measure vision, called MLSDT, in people with normal sight or vision loss from Stargardt disease or geographic atrophy (a type of advanced age-related macular degeneration). Results will help doctors better understand how well patients can see.
Hear when a new Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.